LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 102 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $214,420 | -32.6% | 215,000 | 0.0% | 0.01% | -50.0% |
| Q1 2024 | $318,200 | +35.8% | 215,000 | 0.0% | 0.02% | +100.0% |
| Q4 2023 | $234,350 | -7.6% | 215,000 | 0.0% | 0.01% | -11.1% |
| Q3 2023 | $253,700 | -16.3% | 215,000 | 0.0% | 0.01% | -35.7% |
| Q2 2023 | $303,150 | -6.0% | 215,000 | 0.0% | 0.01% | -22.2% |
| Q1 2023 | $322,500 | +28.2% | 215,000 | 0.0% | 0.02% | +5.9% |
| Q4 2022 | $251,550 | +3.5% | 215,000 | 0.0% | 0.02% | -29.2% |
| Q3 2022 | $243,000 | -28.5% | 215,000 | 0.0% | 0.02% | -33.3% |
| Q2 2022 | $340,000 | +2.7% | 215,000 | 0.0% | 0.04% | -16.3% |
| Q1 2022 | $331,000 | -37.2% | 215,000 | 0.0% | 0.04% | -38.6% |
| Q4 2021 | $527,000 | – | 215,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $52,403,228 | 3.69% |
| Raffles Associates | 1,536,946 | $2,305,419 | 3.14% |
| Defender Capital, LLC. | 5,136,085 | $7,704,128 | 2.69% |
| Prescott General Partners LLC | 1,851,851 | $2,777,777 | 0.22% |
| DAFNA Capital Management LLC | 140,000 | $210,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $67,500 | 0.05% |
| CTC Capital Management, LLC | 14,100 | $21,150 | 0.04% |
| Diametric Capital, LP | 50,875 | $76,313 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $1,172,649 | 0.03% |
| One68 Global Capital, LLC | 13,377 | $20,066 | 0.03% |